Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02702765
Other study ID # Wilson sCD163
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 2016
Est. completion date February 2022

Study information

Verified date November 2022
Source University of Aarhus
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim is to investigate macrophage activation markers and correlations to liver fibrosis in patients with Wilsons Disease. Researchers wish to investigate associations to neurologic and metabolic liver function. Researchers will assess this by comparing blood samples with fibrosis and liver function analyses. This study provides new insight into macrophages and their involvement in Wilsons Disease.


Recruitment information / eligibility

Status Completed
Enrollment 33
Est. completion date February 2022
Est. primary completion date February 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: - diagnosed with Wilsons disease Exclusion Criteria: -

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Fibroscan
Liver fibrosis will be determined using fibroscan, and reported as changes in the amount of fibrosis in the liver. The fibroscan is a non-invasive procedure
Ultrasound
Ultrasound is a non-invasive procedure
Drug:
Galactose
Galactose elimination capacity is performed to evaluate metabolic liver function. The metabolic liver function test galactose elimination capacity requires a 6-hour fast, the infusion of galactose, blood sampling from the ear lobe, and collection of urine for 4 hours.
Procedure:
Liver biopsy
Histological disease activity at time of diagnosis evaluating if any liver fibrosis
Functional hepatic nitrogen clearance
Functional hepatic nitrogen clearance to evaluate metabolic liver function Functional hepatic nitrogen clearance requires a 12-hour fast, two venflons, the infusion of alanine, and urine sampling for 4 hours

Locations

Country Name City State
Denmark Department of Hepatology and Gastroenterology, Aarhus University Hospital Aarhus

Sponsors (2)

Lead Sponsor Collaborator
University of Aarhus Aarhus University Hospital

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Measurement of the macrophage activation markers sCD163 For the investigations a total of 100 ml of blood is drawn, all stored in a research biobank. Baseline, 1 year, 2 year, 3 year
Primary Measurement of soluble mannose receptor (sMR) For the investigations a total of 100 ml of blood is drawn, all stored in a research biobank. Baseline, 1 year, 2 year, 3 year
Secondary Urinary copper excretion in 24 hour urine collection The patient collects urine for 24 hours at home in a designated container, which is handed out at the department. The container is kept refrigerated and is brought to the control Baseline, 1 year, 2 year, 3 year
Secondary Ultrasound is performed for signs of liver cirrhosis. Ultrasound is a non-invasive procedure. Signs og liver cirrhosis by ultrasound are surface modularity, a smaller liver, heterogeneous echo texture and signs of portal hypertension. Baseline, 1 year, 2 year, 3 year
Secondary Fibroscan is performed to evaluate liver stiffness (fibrosis) Liver fibrosis will be determined using fibroscan, and reported as changes in the amount of fibrosis in the liver. The fibroscan is a non-invasive procedure. Baseline, 1 year, 2 year, 3 year
Secondary Continous Reaction Time to evaluate brain dysfunction Continous Reaction Time is a computerized 10 minutes test that measures and combines motor reaction speed and sustained attention. Baseline, 1 year, 2 year, 3 year
Secondary Galactose elimination capacity is performed to evaluate metabolic liver function The metabolic liver function test Galactose elimination capacity requires a 6-hour fast, the infusion of galactose, blood sampling from the ear lobe, and collection of urine for 4 hours. Baseline, 1 year, 2 year, 3 year
Secondary Histological disease activity at time of diagnosis and liver biopsy, evaluating if any liver fibrosis Liver fibrosis will be also be determined on liver biopsies. Baseline, 1 year, 2 year, 3 year
Secondary Functional hepatic nitrogen clearance to evaluate metabolic liver function Functional hepatic nitrogen clearancerequires a 12-hour fast, two venflons, the infusion of alanine, and urine sampling for 4 hours. It evaluates the metabolic liver function by measuring the clearance of alanine from blod by analyzing the amount og urea in the urine collected 4 hours after the start og the alanine infusion. Baseline, 1 year, 2 year, 3 year
Secondary The Portosystemic Encephalopathy to evaluate brain dysfunction The Portosystemic Encephalopathy test is a 15-minute paper-pencil test battery comprised of 5 sub-tests: Digit Symbol test (DST), Number Connection Test A (NCT-A), Number Connection Test B (NCT-B), Serial Dotting Test (SDOT), and Line Tracing Test (LTT, time and errors). Baseline, 1 year, 2 year, 3 year